Outdoor testing of the photoprotection provided by a new water-based broad-spectrum SPF50+ sunscreen product: Two double-blind, split-face, randomized controlled studies in healthy adults by Granger, C. et al.
OR I G I N A L R E S E A R C H
Outdoor testing of the photoprotection provided
by a new water-based broad-spectrum SPF50+
sunscreen product: two double-blind, split-face,
randomized controlled studies in healthy adults
This article was published in the following Dove Press journal:





1Innovation and Development, ISDIN,
Barcelona, Spain; 2Meteorology Group,
Department of Applied Physics,
University of Barcelona, 08028 Barcelona,
Spain; 3Dermatology Department,
Hospital Universitario Miguel Servet,
Zaragoza, Spain; 4Academia Española de
Dermatología y Venereología, Zaragoza,
Spain; 5Revista Actas Dermo-Sifiliogr
áficas, Zaragoza, Spain; 6Health Sciences,
University of Zaragoza, Zaragoza, Spain
Purpose: Users often under-apply sunscreens, and one of the main reasons cited for this is
the cosmetic formulation of the product. To address this, we developed a water-based
sunscreen. The product underwent standard laboratory testing (ISO 24444: 2010) and was
determined as sun protection factor (SPF) 50+. However, such laboratory testing does not
take into account environmental factors of in-use conditions that could potentially affect
sunscreen efficacy, particularly of new cosmetic formulations. We aimed to test this product
in conditions more representative of real-life solar exposure, to confirm its reported labora-
tory efficacy.
Methods: Two double-blind, randomized, controlled, split-face intra-individual studies were
conducted during summer months in Barcelona. One study compared the product against an
SPF15 control (reference standard P3 of ISO 24444: 2010), while the other compared against
an SPF50+ control (another commercially available sunscreen). A technician applied the
products before sun exposure: investigational product (IP) to one half of the face and the
respective control product to the other. Subjects spent 4–6 hrs outdoors performing quiet
activities, and sunscreens were reapplied at 2 hourly intervals. A dermatologist clinically
scored facial erythema at baseline and at 24 hrs.
Results: Sixty-five subjects were included in total. In both studies, skin treated with the IP showed
no significant increase in clinical erythema scoring at 24 hrs. There were statistically significant
differences between the IP and the SPF15, but not between the IP and the SPF50+ control. SPF15
did not protect all subjects against solar-induced erythema.
Conclusion: These outdoor studies confirm the efficacy of this new SPF50+ water-based
sunscreen in conditions that closer represent real-life sun exposure.
Keywords: erythema, sunburn, sunscreen, photoprotection, real-life testing
Introduction
Solar radiation induces acute and chronic damage to the skin and is potentially
carcinogenic.1,2 Despite efforts to increase awareness,3 sunburn prevalence remains
high. A 2012 report by the Centre for Disease Control and Prevention found that
50% of adults and 66% of white adults aged 18–29 in the USA reported at least one
sunburn in the previous 12 months.4 Ultraviolet (UV) B induces sunburn, and DNA
may be damaged directly via UVB-induced generation of cyclobutane pyrimidine
dimers and thymine dimers, or indirectly via UVA-induced generation of reactive
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oxygen species.2 Epidemiological evidence shows an asso-
ciation between cumulative sun exposure and non-
melanoma skin cancers,2 and between episodic severe
sunburn and melanoma.5,6
Photoprotection is therefore recommended to
minimize skin damage.7 Key approaches are seeking
shade, wearing protective clothing, and using sunscreen
on exposed areas. Sunscreens are often the main mode of
protection used in outdoor activities,4,8 yet despite this
reliance, many users continue to under-apply sunscreens
at quantities below the recommended 2 mg/cm2.9,10
A reluctance to apply abundant sunscreen has been attrib-
uted to cosmetic aspects, such as oiliness, stickiness, or
unpleasant texture.11,12 To address this, we developed
a water-based broad-spectrum sunscreen product (ISDIN
Fusion Water) formulated to absorb quickly and avoid
residues, that would be pleasant to use while still provid-
ing very high UV protection.
This new product was tested using the international
standard laboratory method (ISO 24444: 2010)13 and
determined to have a sun protection factor (SPF) of 50+.
SPF is the well-established metric for sunscreen protection
against sunburn, determined on in vivo laboratory testing.
Although SPF has become the accepted worldwide stan-
dard for measuring sunscreen efficacy, there remain some
controversies regarding the method and the effects of real
conditions of use on the protection achieved in outdoor
conditions.14,15 SPF testing aims to induce erythema as
rapidly as possible13,16 using solar simulators that emit UV
radiation in the region of 290–400 nm, while added filters
cut off radiation below 290 nm and beyond UV wave-
lengths; consequently, the effects of infrared or visible
radiation on skin are not taken into account.2,17
Furthermore, in real-life conditions, the qualities of the
product once applied to the skin may be influenced by the
environment (eg, temperature).18,19 Unlike more well-
studied, classical oil-based products, there was no evi-
dence on how this newly developed water-based product
would behave in real life. Our aim was to assess the
efficacy of this product in conditions that would closer
represent real-life solar exposure, to provide a more robust
level of evidence on its efficacy outside the laboratory,
while still ensuring adequate application. Our hypothesis
was that the investigational product (IP) would provide
better protection than the SPF15 and comparable protec-
tion to the SPF50+ control, but we wanted to establish this
in a non-laboratory setting, in case the new product
behaved unpredictably in real-life conditions.
Materials and methods
Study design
Two double-blind, split-face, randomized controlled stu-
dies were designed to assess the clinical efficacy in pre-
venting erythema of a new water-based broad-spectrum
SPF50+ sunscreen product using established sunscreen
products as controls. The studies were designed in parallel,
but conducted in different months for logistical reasons,
from July to September 2018, in Barcelona, Spain. They
were designed as independent studies but used a similar
methodology.
IP and controls
The IP was a combination of lipophilic organic sun filters:
ethylhexyl methoxycinnamate, butyl methoxydibenzoyl-
methane, ethyl hexyl triazone, and a physical filter: titanium
dioxide, formulated in a water-based innovative galenic for-
mulation. The IP was compared in the two separate studies
against an SPF15 sunscreen (reference standard P3 of ISO
24444: 2010,13 containing the solar filters ethylhexyl methox-
ycinnamate, butyl methoxydibenzoylmethane and phenylben-
zimidazole sulfonic acid) and a different SPF50+ sunscreen
from the same manufacturer (solar filters: octocrylene, butyl
methoxydibenzoylmethane, bis-ethylhexyloxyphenolmethox-
yphenyl triazine and titanium dioxide). The SPF50+ control
was chosen in the absence of a reference standard for SPF50+
assessment.
Subjects
The inclusion criteria for the two studies were generally
equivalent: healthy male and female adults aged 18–60
years old (18–55 in study 2), of all skin types, with
Fitzpatrick phototype I–IV (I–III in study 2), ITA (indivi-
dual typology angle) over 28 on the back, who were at
least occasional users of cosmetic products or sun care
products. The studies excluded those with skin marks
that could interfere with assessment (pigmentation disor-
ders, scarring, large number of nevi, etc.), history of aller-
gic reactions to similar products, history of skin cancer or
dysplastic nevi, active facial skin disease, endocrine dis-
ease, immunosuppressive conditions or medications, and
any treatments (topical or oral, including food supple-
ments) that may affect skin pigmentation or reactions.
Pregnant or breastfeeding women were not allowed.
Twenty-nine subjects were initially included in study 1
(vs SPF15), and 38 in study 2 (vs SPF50+). Study 1
compared against SPF15 and was conducted in
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September, and study 2 compared against SPF50+ and was
conducted in July. As stated above, the two studies were
designed in parallel, as independent studies involving
similar methodology, and due to logistical reasons only
were conducted in this order.
Both studies were performed on sunny days with clear
skies or low cloud cover; if there was cloudy weather on
the planned study day, the studies were postponed. Both
were split-face design, with the IP applied to one hemiface
and SPF15 or SPF50+ control to the other. The side of the
face to be treated with each product was allocated accord-
ing to a randomization table. The study technician applied
2 mg/cm2 of each product using a finger stall 30 mins
before exposure. In the first 4–5 subjects, a Wood lamp
was used to assess even coverage with the sunscreen
products after the first application.
Study 1 (vs SPF15) lasted 6 hrs (approximately 10.30
am–12.30 pm and 1.30 pm–5.30 pm, with a 30-min break
between) and was conducted on the sun terrace of a fitness
center. Subjects performed free quiet activities (no water-
related or excessive sweat-inducing activities were planned).
Subjects were instructed to request reapplication of sunsc-
reen products as they felt necessary, and the technician then
applied them on their request, after the first 2 hrs.
Study 2 (vs SPF50+) was conducted in a public square
over 4 hrs. A subgroup of four subjects began the study and
conducted prescribed activities at 30-min intervals: walking,
sitting (reading/listening to music), and lying face upward.
They spent 2 hrs outdoors (10 am–12 noon) then sunscreen
was reapplied during a 30-min indoor break, before a further 2
hrs’ exposure (12.30–2 pm). However, the investigator judged
that the period of exposure was too long during critical hours,
so the protocol was modified for the remaining 25 subjects, to
start and finish earlier in the day (9 am–1 pm) with 5-
min shade breaks upon request, and reapplication of sunscreen
products upon subjects’ request any time after the first 2 hrs.
Subjects were also allowed to perform the permitted activities
freely provided they respected the study constraints.
Erythemal UVB radiation
Cumulative doses of erythemal UVB radiation were
determined from erythemal irradiances measured
with a broadband YES UVB-1 pyranometer (Yankee
Environmental Systems, MA, USA) installed on the roof of
the faculty of physics of the University of Barcelona. The
instrument belongs to the Radiometric Network of the
Spanish Meteorological Service (AEMET). The pyranometer
has a spectral response close to the erythema action spectrum20
and measures the solar radiation received by a horizontal sur-
face from the whole sky. The UV index,21 a tool developed to
inform the public of the potential erythemal effect of solar
radiation, was determined from these measurements. Bech
et al22 previously reported on the climatology and UV index
in this location.
Endpoints
The objective of the study was to assess the efficacy of the IP
in preventing erythema in a settingmore representative of real-
life solar exposure. The primary endpoint of both studies was
the erythema score following outdoor sun exposure, based on
clinical examination of facial erythema at baseline and at 20±4
hrs postexposure. In study 1 (vs SPF15) a scale of 0–9 was
used, with 0 being no erythema and 9 being very intense
erythema,23 while study 2 used a scale of 0–424,25 (Table 1).
Subjects were also questioned and examined by
a dermatologist or responsible technician regarding local
skin reactions at these same time points and given an indivi-
dual observation sheet to record any symptoms. The derma-
tologists and technicians who assessed erythema, as well as
the subjects, were blinded to the treatment allocations.
As a secondary objective, we were interested to see if the
study design would discriminate between the photoprotec-
tive ability of our water-based IP and the control sunscreens.
Statistical analysis
Means and SD were calculated for clinical scoring.
Wilcoxon signed rank test was used to compare the
Table 1 Clinical erythema scale
Study 1 Study 2
Score Description Score Description
0 No erythema 0 No erythema
1 Very slight erythema (barely perceptible) 1-2-3 Very slight erythema
2 Slight erythema (well defined) 4-5 Slight erythema
3 Moderate erythema 6-7 Moderate erythema
4 Strong erythema 8-9 Marked erythema
Dovepress Granger et al
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differences between the score at baseline and 20±4 hrs,
between the IP and the respective control product. The
results of the two studies were independent and not com-
pared with each other. SPSS v. 6.1.3. (study 1) and v.3.4.3
(study 2) were used to perform the statistical analysis;
P<0.05 was considered statistically significant.
Ethical consideration
All subjects provided signed informed consent. The studies
were performed taking into account the principles of Good
Clinical Practice (E6: CPMP/ICH/135/95) and the
Declaration of Helsinki 1964 and its subsequent amend-
ments. Due to the nature of the IP being cosmetic rather
than medicinal, ethics committee approval was not required.
Results
The details of the study subjects are presented in Table 2.
The distribution by phototype was, for study 1: 0%
Fitzpatrick type I, 32% type II, 66% type III, 3% type
IV; for study 2: 7% type I, 41% type II, 52% type III.
UV doses
In study 1, the maximum UV index was 5.9, and the mean
(±SD) total cumulative dose (6 hrs) of erythemal UVB
radiation was 200.3±14.8 mJ/cm2. Sunscreens (IP and con-
trol) were applied a mean 3.2 times (min 2–max 5) during
the 6-hr solar exposure period. In study 2, the maximum UV
index during study hours was 8.5, and the mean total
cumulative dose (4 hrs) of erythemal UVB radiation was
164.9±15.8 mJ/cm2. Sunscreens were applied a mean 1.7
times (min 1–max 2) during the 4-hr exposure period.
Erythema
In both studies, in skin treated with the IP, there was no
statistically significant difference in erythema score from
baseline to 20±4 hrs after exposure (Tables 3 and 4).
In study 1, the erythema score at 20±4 hrs was not sig-
nificantly different from baseline for the IP (mean erythema
score increase of 6%, P=0.66) but was significantly higher for
the SPF15 product (mean erythema score increase of 16%,
P<0.01). Only 3 subjects had an increase in the erythema
score (of 1 point) for the area covered with the IP, vs 9 subjects
for the area covered with the SPF15 (8 with an increase of 1
point and 1 with an increase of 2 points) (Table 5).
In study 2, there was no statistically significant differ-
ence in erythema score at 20±4 hrs between the IP and the
control SPF50+ (P=0.45).
A post-hoc analysis (Wilcoxon test) by Fitzpatrick skin
type subgroups (type II vs type III in study 1 and type I+II
vs type III in study 2) revealed no statistically significant
differences between groups for changes at 24 hrs.
Tolerability
In study 1, no skin or eye reactions were reported. In study
2 (vs SPF50+), no skin reactions occurred. Two subjects
reported ocular itching with both the IP and the control
sunscreen (bilateral itch), and 2 subjects had itching with
the control sunscreen but not the IP (unilateral).
Discussion
These two studies show that, with the recommended appli-
cation quantity (2 mg/cm2), following 4–6 hrs of outdoor
sun exposure in a Mediterranean location in summer, the
investigational water-based SPF50+ sunscreen product
prevented solar erythema – indicative of inflammation –
in individuals with Fitzpatrick phototypes I–IV, which is of
clinical interest regarding long-term skin health. The IP
was superior to SPF15 and had a comparable level of
photoprotection to an existing SPF50+, confirming the
product provided a very high level of sun protection.
It was somewhat surprising to observe that in the
SPF15 control group, there was a statistically significant
increase in erythema (+16%), which could suggest that
SPF15 is insufficient under such circumstances of summer
weather and in subjects with a majority (66%) Fitzpatrick
phototype III. Assessing the minimum SPF required to
Table 2 Study subject characteristics
Study 1 Study 2
No. participants 38 29
Withdrewa 0 1
Excludedb 0 1
Included in analysis 38 27
Age, mean (min–max) 43 (21–59) 39 (18–55)
Sex
Female 30 (79%) 17 (63%)
Male 8 (21%) 10 (37%)
Fitzpatrick phototype
I 0 (0%) 2 (7%)
II 12 (32%) 11 (41%)
III 25 (66%) 14 (52%)
IV 1 (3%) NA
Notes: aSubject withdrew for personal reasons unrelated to study. bSubject
excluded for protocol noncompliance.
Abbreviation: NA, not applicable (subjects with skin phototype IV were not
included in this study).
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prevent erythema was not the primary endpoint of this
study, but it is interesting to reflect on this finding within
the context of the recommendations from established asso-
ciations: while some recommend a minimum SPF of 15,,26
others suggest SPF30.27,28 Indeed, dermatologists may
simply recommend “the highest possible protection” to
their patients.7 Our findings point toward the latter options
being more appropriate, although establishing such
a recommendation was not our objective. Nonetheless,
any reduction in erythema is viewed as beneficial due to
its association with inflammatory processes.
The uniqueness of this study lies in its design. Being an
outdoor study, it allowed us to include the full spectrum of
solar radiation, including visible and infrared light.2 In
addition, the split-face design minimized variability and
allowed us to position the product with reference to exist-
ing sun protection products, while maintaining scientific
standards that ensured a fair comparison of the tested
products, and ensuring application in line with recom-
mended methods of use. Although study 2 (vs SPF50+)
was carried out in July when the UV radiation is higher
than that in September, shorter exposure periods outside of
solar noon resulted in smaller doses.
While most studies testing sunscreen efficacy are con-
ducted indoors, there are very few studies comparing sunsc-
reens in real-life conditions of solar radiation exposure.
A recent study by Williams et al24 assessed in 199 healthy
men and women in a single-center randomized controlled
split-face double-blind study the sunburn protection provided
by an SPF100+ vs SPF50+ sunscreen in actual use conditions.
They concluded that the SPF 100+ sunscreen was significantly
more effective in protecting against sunburn than SPF 50+.24
Those results support the idea that higher SPFs may provide
meaningfully improved photoprotection in real conditions of
use by compensating for users’ under-application (in the study,
subjects applied around 1 mg/cm2, in contrast to the
Table 5 Increases in erythema scores at 24 hrs
Study Product No increase Increase by 1 point Increase by ≥2 points
Study 1 (N=38) IP 35 3 0
SPF15 29 8 1
Study 2 (N=27) IP 22 5 0
SPF50+ 20 6 1
Abbreviations: IP, investigational product; SPF, sun protection factor.
Table 3 Clinical erythema scoring results from study 1 (vs SPF15)
Clinical score,a mean±SD
Baseline T24b Mean % change
IP 3.05±1.43 3.08±1.30 ↑6%±24% P=0.65 vs baselinec
Reference SPF15 2.89±1.37 3.16±1.26 ↑16%±32% P<0.01 vs baselinec
P=0.02 vs reference SPF15c
Notes: aScale of 0–9. bT24=20±4 hrs from the end of solar exposure period. cWilcoxon signed rank test; P<0.05 statistically significant.
Abbreviations: IP, investigational product; SPF, sun protection factor.
Table 4 Clinical erythema scoring results from study 2 (vs SPF50+)
Clinical score,a mean±SD
Baseline T24b Mean % change
IP 0.3±0.5 0.5±0.6 ↑5%±10% P=0.06 vs baselinec
Reference SPF50+ 0.4±0.5 0.7±0.6 ↑7%±14% NP
P=0.14 vs reference SPF50+c
Notes: aScale of 0–4. bT24=20±4 hrs from the end of solar exposure period. cWilcoxon signed rank test; P<0.05 statistically significant.
Abbreviations: IP, investigational product; NP, not performed; SPF, sun protection factor.
Dovepress Granger et al
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recommended 2mg/cm2). Our study, in comparison, had some
not dissimilar findings in that the investigational SPF50+
product was superior in efficacy to the SPF15 control product;
however, in contrast to the previous study, this difference
cannot be attributed to suboptimal use, since both products
were applied by a trained technician at 2mg/cm2 and reapplied
at approximately 2 hourly intervals (a mean 1.7 times in the 4-
hr study and 3.2 times in the 6-hr study).
The studies reported here demonstrate that the product
protects against erythema, which is known to be induced
principally by UVB and UVA-II radiation.2 Although our
study took place outdoors, and therefore included the full
naturally occurring range of light, it did not specifically
assess UVA-induced damage; however, the IP has an
in vivo UVA protection factor of 20.3.
One limitation of the study design is that the two
clinical assessments used different scales (0–9 and 0–4,
respectively). Use of the same scale in both studies would
have allowed a clearer direct comparison of results. This
difference was due to the two studies being conducted by
two independent contract research organizations, and the
fact that there is no established standard scale for quanti-
fication of solar-induced erythema. However, a previous
study23 concluded that such visual methods, namely, a 10-
point scale, were “sensitive, reliable and reproducible
within a testing institution”. It is interesting to note that,
while a 10-point scale may be described as more sensitive
than a 5-point scale, and did indeed pick up a change in
SPF15-treated skin, its use did not result in finding
a significant change in IP-treated skin in the same study.
The interpretation of the results can be applied to
similar settings, that is, those permitting a variety of
quiet outdoor activities. Further studies are planned to
assess the product’s efficacy under extreme UV conditions,
and the product has previously undergone testing in wet-
skin, with a result similar to that in the standard SPF
testing (unpublished data).
The results of these outdoor studies also demonstrate
that the study design used was able to discriminate
between an SPF15 sunscreen and the investigational
SPF50+ sunscreen in terms of clinical photoprotective
capacity.
This water-based broad-spectrum SPF50+ sunscreen has
been demonstrated to provide very high protection against
solar-induced erythema. Naturally, this does not abrogate
the established sun-safe advice to continue to seek shade
and use protective clothing; rather, this product can power-
fully bolster such approaches, and along with ongoing user
education,29 optimize solar skin protection.30,31 As sunsc-
reen is often the main preventive strategy employed,29 it is
essential that the product used be as highly effective as
possible and that the texture of the formulation encourage
adequate and frequent reapplication of the product. As
Wang et al32 concluded, the best sunscreen is the one that
is actually used.
Conclusion
In outdoor conditions in Mediterranean summer sun, this
water-based broad-spectrum SPF50+ sun protection product
had a very high photoprotective effect: a level comparable to
an existing SPF50+ sunscreen and superior to the SPF15
reference sunscreen, even in phototype III and IV skin.
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